Managing Momentum With Rezolute Bio's Nevan Charles Elam, JD
![23_01_BPO_BusBiotech_1200x628_Ep163 23_01_BPO_BusBiotech_1200x628_Ep163](https://vertassets.blob.core.windows.net/image/e38e9753/e38e9753-c037-4489-8031-23cb386667ff/375_250-23_01_bpo_busbiotech_1200x628_ep163.png)
Since we last spoke in the Spring of 2021, Nevan Charles Elam, JD has managed to advance both of small-but-mighty Rezolute Bio's candidates onto the next phases of their journey. This year, on the back of a $130 million investment, Rezolute Bio is prepping its RZ358 candidate, a monoclonal antibody for congenital hyperinsulinism, for a pivotal phase 3 trial. On this week's episode of the Business of Biotech, we're settling in for an interrogation of Elam on the management principles of maintaining multi-candidate clinical momentum among highly disparate candidates and raising big dollars as a small biotech.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.